Skip to content

Evaluation for the protective effect of pre-liver transplant CRE decolonization against CRE infection post liver transplantation: a single center, randomized, case-control study

Evaluation for the protective effect of pre-liver transplant CRE decolonization against CRE infection post liver transplantation: a single center, randomized, case-control study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100048418
Enrollment
Unknown
Registered
2021-07-06
Start date
2021-07-01
Completion date
Unknown
Last updated
2022-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infection

Interventions

Experimental group:Decolonization with oral antibiotics and probiotics
Control group:None

Sponsors

First Affiliated Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 18-75 years; 2. Patients with end-stage liver disease who plan to undergo liver transplantation; 3. Two preoperative rectal swab tests or stool culture suggest CRE colonization; 4. Stable vital signs: no need for vasoactive drugs to maintain blood pressure; under resting state, oxygen saturation > 92%; 5. Be able to understand and sign the informed consent; 6. Patients of childbearing age agree to take effective contraceptive measures during the study period.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating patients; 2. Patients with known CRE infection; 3. Symptoms of intestinal infection such as fever and diarrhea within 2 weeks; 4. Patients who have received or are receiving antibiotics including carbapenems, aminoglycosides, tigecycline, polymyxin, fosfomycin and ceftazidime avibactam within 2 weeks; 5. Patients with hepatic encephalopathy grade III-IV; 6. The patient needs urgent liver transplantation and cannot complete 7-14 days of decolonization treatment; 7. Allergic to gentamicin, polymyxin, probiotics, or unable to take oral drugs; 8. Patients with colon or jejunostomy; 9. Active gastrointestinal bleeding; 10. Participate in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Incidence of CRE infection;

Secondary

MeasureTime frame
Overall survival;Incidence of all infections;Sensitivity to gentamicin, polymyxin, tigecycline (MIC);Acute rejection occurs with in 30 days after transplantation;The success rate and recurrence rate of decolonization;Emergence of new drug resistance in colonized CRE;Intestinal colonization by other resistant bacteria (VRE, ESBL, etc.);

Countries

China

Contacts

Public ContactZhang Wei

First Affiliated Hospital, Zhejiang University School of Medicine

zhangweigyz@163.com+86 571 87236195

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026